sitafloxacin has been researched along with Mycobacterium-Infections* in 2 studies
2 other study(ies) available for sitafloxacin and Mycobacterium-Infections
| Article | Year |
|---|---|
Successful treatment of cutaneous Mycobacterium chelonae infection by switching from levofloxacin to sitafloxacin.
Topics: Anti-Bacterial Agents; Fluoroquinolones; Humans; Levofloxacin; Mycobacterium chelonae; Mycobacterium Infections; Mycobacterium Infections, Nontuberculous; Skin Diseases, Bacterial | 2023 |
[Measurement of sitafloxacin MIC for Mycobacterium avium complex and application for treatment of pulmonary nontuberculous mycobacteriosis].
Treatment for pulmonary nontuberculous mycobacteriosis is difficult. Since current treatment has limitation, new application is needed. Fluoroquinolone is one of candidates. We have investigated the feasibility of sitafloxacin (STFX). At first, the drug of MIC (minimum inhibitory concentration) was determined by the methods based on BrothMIC NTM. The MICs of STFX, moxifloxacin (MFLX), gatifloxacin (GFLX) were low. On contrast, the MICs of garenoxacin (GRNX) and tosufloxacin (TFLX) were high. Two cases of pulmonary Mycobacterium avium-intracellulare complex (MAC) disease were treated by STFX-contained regimen. In all cases of pulmonary MAC disease, improve of symptoms and chest CT images were attained. Adverse events were slight. These MIC studies and case reports suggest that STFX might have excellent in vitro and in vivo antimicrobial activities against MAC and is considered to be a candidate for the medication against pulmonary MAC disease. Topics: Aged; Anti-Bacterial Agents; Female; Fluoroquinolones; Humans; Microbial Sensitivity Tests; Middle Aged; Mycobacterium avium Complex; Mycobacterium Infections | 2014 |